| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... Journal of clinical oncology 33 (25), 2780-2788, 2015 | 2565 | 2015 |
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ... Journal of Clinical Oncology 34 (22), 2619, 2016 | 541 | 2016 |
| Weighted gene coexpression network analysis: state of the art W Zhao, P Langfelder, T Fuller, J Dong, A Li, S Hovarth Journal of biopharmaceutical statistics 20 (2), 281-300, 2010 | 367 | 2010 |
| Network neighborhood analysis with the multi-node topological overlap measure A Li, S Horvath Bioinformatics 23 (2), 222-231, 2007 | 224 | 2007 |
| Aromatase expression predicts survival in women with early-stage non–small cell lung cancer V Mah, DB Seligson, A Li, DC Márquez, II Wistuba, Y Elshimali, ... Cancer research 67 (21), 10484-10490, 2007 | 169 | 2007 |
| Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score JS Lam, DB Seligson, H Yu, A Li, M Eeva, AJ Pantuck, G Zeng, S Horvath, ... BJU international 98 (2), 445-451, 2006 | 101 | 2006 |
| Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected … HK Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R ... Journal of Clinical Oncology 32 (5s), suppl; abstr 9029, 2014 | 97 | 2014 |
| Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants OQP Yin, N Gallagher, A Li, W Zhou, R Harrell, H Schran The Journal of Clinical Pharmacology 50 (2), 188-194, 2010 | 96 | 2010 |
| Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating … HL Kaufman, RHI Andtbacka, FA Collichio, T Amatruda, NN Senzer, ... Journal of Clinical Oncology 32 (15_suppl), 9008a-9008a, 2014 | 65 | 2014 |
| A group sequential Holm procedure with multiple primary endpoints Y Ye, A Li, L Liu, B Yao Statistics in medicine 32 (7), 1112-1124, 2013 | 60 | 2013 |
| Network module detection: Affinity search technique with the multi-node topological overlap measure A Li, S Horvath BMC research notes 2, 1-14, 2009 | 53 | 2009 |
| Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB … I Puzanov, MM Milhem, RHI Andtbacka, DR Minor, O Hamid, A Li, J Chou, ... Journal of clinical oncology 33 (15_suppl), 9063-9063, 2015 | 48 | 2015 |
| Elevated MED28 expression predicts poor outcome in women with breast cancer NK Yoon, EL Maresh, Y Elshimali, A Li, S Horvath, DB Seligson, D Chia, ... BMC cancer 10, 1-9, 2010 | 32 | 2010 |
| Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV … RHI Andtbacka, FA Collichio, T Amatruda, N Senzer, J Chesney, ... Journal for ImmunoTherapy of Cancer 2, 1-2, 2014 | 30 | 2014 |
| Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for … RHI Andtbacka, M Chastain, A Li, M Shilkrut, MI Ross Journal of Clinical Oncology 33 (15_suppl), TPS9094-TPS9094, 2015 | 24 | 2015 |
| Higher expression levels of 14-3-3σ in ductal carcinoma in situ of the breast predict poorer outcome NK Yoon, DB Seligson, D Chia, Y Elshimali, G Sulur, A Li, S Horvath, ... Cancer Biomarkers 5 (4-5), 215-224, 2009 | 20 | 2009 |
| Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma JJ Nemunaitis, RH Andtbacka, M Ross, T Amatruda, J Chesney, ... Annals of Oncology 25, iv382, 2014 | 9 | 2014 |
| Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in … I Puzanov, M Milhem, R Andtbacka, D Minor, O Hamid, A Li, ... Journal for ImmunoTherapy of Cancer 1, 1-2, 2013 | 9 | 2013 |
| Efficacy and safety of ATA129, partially matched allogeneic third-party Epstein-Barr virus-targeted cytotoxic T lymphocytes in a multicenter study for post-transplant … S Prockop, A Li, RA Baiocchi, N Bunin, KM Mahadeo, ER Nemecek, ... Blood 130, 4520, 2017 | 4 | 2017 |
| Tissue microarrays: construction and utilization for biomarker studies SM Mumenthaler, N Yoon, A Li, V Mah, G Chang, F Nooraie, Y Elshimali, ... Methods of Cancer Diagnosis, Therapy and Prognosis: Breast Carcinoma, 217-234, 2008 | 3 | 2008 |
Steve HorvathProfessor of Human Genetics and Biostatistics, University of California, Los AngelesVerified email at mednet.ucla.edu
